250mg Gefticip Gefitinib Tablets

250mg Gefticip Gefitinib Tablets Specification

Indication
First-line therapy for EGFR mutation-positive advanced NSCLC

Packaging Type
Blister pack / Bottle

Life Span
24 months from date of manufacture

Salt Composition
Gefitinib 250mg

Dosage Form
Solid (Tablet)

Origin of Medicine
India

Brand Name
Gefticip

Pacakaging (Quantity Per Box)
30 tablets

Drug Type
Targeted therapy (EGFR inhibitor)

Ingredients
Gefitinib

Physical Form
Tablets

Function
Anti-cancer agent; inhibits epidermal growth factor receptor (EGFR)

Recommended For
Non-Small Cell Lung Cancer (NSCLC)

Dosage
250mg per tablet

Dosage Guidelines
As directed by the oncologist or physician

Suitable For
Adults

Quantity
30 tablets per bottle

Storage Instructions
Store below 30C, protect from light and moisture

Side Effects
Rash, diarrhea, nausea, loss of appetite, dry skin

Product Code
Gefticip-250

Administration Route
Oral

Shape
Round

Color
White to off-white

Regulatory Approval
WHO-GMP certified manufacturing

Prescription/Non-Prescription
Prescription only

Contraindications
Hypersensitivity to Gefitinib or any excipients

Patient Counseling Information
Avoid pregnancy and breastfeeding while on therapy; regular monitoring advised

250mg Gefticip Gefitinib Tablets Trade Information

Minimum Order Quantity
10 Pieces

Supply Ability
5000 Pieces Per Month

Delivery Time
7 Days

About 250mg Gefticip Gefitinib Tablets

Dose/Strength	250 mg
Manufacturer	Cipla Ltd
Packaging Type	Box
Pack Size	30 Tablets
Brand Name	Gefticip
Composition	Gefitinib
Treatment	Treatment of Non Small Cell Lung Cancer

Gefticip Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.

How Gefticip 250mg Works

Gefticip 250mg tablets function as a targeted therapy by inhibiting the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. By blocking EGFR, Gefitinib hinders the proliferation of cancer cells, making it highly effective for patients with EGFR mutation-positive advanced NSCLC.

Proper Administration and Dosage Guidelines

Gefticip is designed for oral administration, with each tablet containing 250mg of Gefitinib. It should be taken once daily or as specifically instructed by your oncologist. Adhering to the prescribed schedule maximizes therapeutic benefit while reducing the risk of side effects.

Storage and Packaging

Each bottle or blister pack contains 30 tablets, formulated for optimal stability. Store the medication below 30C, shielded from direct light and moisture, to maintain efficacy throughout its 24-month shelf life. Always keep the product out of reach of children.

FAQ's of 250mg Gefticip Gefitinib Tablets:

Q: How should Gefticip 250mg Gefitinib Tablets be taken?

A: Gefticip 250mg tablets are intended for oral use only. Take one tablet daily, or as advised by your oncologist. Swallow the tablet with water and avoid crushing or chewing it. Consistency in administration time each day is encouraged.

Q: What is Gefticip 250mg used for?

A: Gefticip 250mg Gefitinib Tablets are primarily used as first-line therapy for adults with advanced non-small cell lung cancer (NSCLC) that is EGFR mutation-positive. Your oncologist will determine if Gefticip is suitable for your specific cancer type.

Q: When can patients expect to see the benefits of Gefticip?

A: The therapeutic effects of Gefticip may vary depending on individual response and disease progression. It is important to attend follow-up appointments with your oncologist, who will monitor your response through scheduled assessments and adjust your treatment as necessary.

Q: Where is Gefticip 250mg manufactured and is it approved?

A: Gefticip 250mg is manufactured in India by a WHO-GMP certified facility, ensuring compliance with global quality standards for safety and efficacy.

Q: What side effects are associated with Gefticip?

A: Common side effects may include rash, diarrhea, nausea, loss of appetite, and dry skin. Promptly inform your healthcare provider if you experience severe or persistent side effects for further guidance.

Q: Who should not take Gefticip 250mg?

A: Gefticip should not be used by patients with known hypersensitivity to Gefitinib or any of its excipients. Pregnant and breastfeeding women should avoid this medication due to potential risks.

Q: How should Gefticip be stored for best results?

A: Store Gefticip tablets below 30C, in a dry place protected from light and moisture. Ensure the bottle or blister pack is tightly closed and out of reach of children.